Skip to content

US · LNSR · MEDICAL - EQUIPMENT & SERVICES

LENSAR Inc (LNSR) intrinsic value and stock valuation

$4.46as of 2026-11-21 · Mkt cap 71.6M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LENSAR Inc DCF and intrinsic value

InvestorsCraft values LNSR with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from LNSR’s statements →

LENSAR Inc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Equipment & Services Orlando, FL 32826 lensar.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$58.4M+17.2% 5y CAGRd
20182025
Net income
-$-34.28M
20182025
Free cash flow
-$-14.91M
20182025
Total equity
-$-26.02M
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$58.4M$53.5M$42.2M$35.4M$34.5M
Operating income-$-24.58M-$-10.66M-$-12.23M-$-20.18M-$-19.65M
Net income-$-34.28M-$-31.4M-$-14.38M-$-19.91M-$-19.6M
EPSd-$-2.87M-$-2.73M-$-1.31M-$-1.96M-$-2.09M
Operating cash flow-$-14.83M-$-2.27M-$-9.66M-$-14.86M-$-8.97M
Capital expenditure-$-80K-$-160K-$-240K-$-120K-$-350K
Free cash flow-$-14.91M-$-2.43M-$-9.89M-$-14.97M-$-9.32M
Total assets$71.4M$66.3M$69.6M$55.8M$66.5M
Total debt$2.73M$2.61M$2.31M$2.8M$3.31M
Net debt-$-10.24M-$-13.65M-$-18.31M-$-11.87M-$-28.32M
Total equity-$-26.02M$18.7M$47.2M$42M$54.9M
Cash and short-term investments$18M$22.5M$24.1M$14.7M$31.6M
Income statement
20252024202320222021
Revenue$58.4M$53.5M$42.2M$35.4M$34.5M
Cost of revenue$31.3M$27.6M$21.1M$15.4M$16.6M
Gross profit$27.1M$25.9M$21.1M$20M$17.8M
Research and development expenses$5.62M$5.33M$6.14M$11.8M$12.4M
Selling, general and administrative expenses$45.2M$26.5M$26.1M$27.2M$23.9M
Other expenses$920K$4.7M$1.1M$1.15M$1.24M
Operating expenses$51.7M$36.5M$33.3M$40.1M$37.5M
Cost and expenses$83M$64.2M$54.4M$55.5M$54.1M
Interest income$90K$100K$90K$20K$30K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$4.5M$3.93M$3.52M$3.41M$2.76M
Ebitda-$-29.78M-$-3M-$-10.87M-$-16.51M-$-16.84M
Operating income-$-24.58M-$-10.66M-$-12.23M-$-20.18M-$-19.65M
Total other income/expenses, net-$-9.7M-$-20.74M-$-2.15M$260K$50K
Income before tax-$-34.28M-$-31.4M-$-14.38M-$-19.91M-$-19.6M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-34.28M-$-31.4M-$-14.38M-$-19.91M-$-19.6M
Weighted average shares outstanding$12M$11.5M$11M$10.2M$9.37M
Weighted average diluted shares outstanding$12M$11.5M$11M$10.2M$9.37M
Balance sheet
20252024202320222021
Cash and short-term investments$18M$22.5M$24.1M$14.7M$31.6M
Net receivables$6.38M$6.48M$4.32M$6.24M$4.99M
Inventory$21.5M$11.4M$15.7M$11.7M$6.49M
Total current assets$46.8M$42M$46.4M$33.7M$44.8M
Property, plant and equipment, net$510K$660K$10.3M$6.88M$7.45M
Goodwill and intangible assets$5.19M$6.11M$11M$12.1M$10.9M
Long-term investments$0.00$1.16M$490K$440K$0.00
Total non-current assets$24.7M$24.3M$23.1M$22.1M$21.7M
Total assets$71.4M$66.3M$69.6M$55.8M$66.5M
Accounts payable$19M$6M$4.01M$5.42M$2.69M
Short-term debt$750K$520K$560K$530K$510K
Deferred revenue$3.07M$1.68M$1.35M$770K$900K
Total current liabilities$40.6M$15M$11.6M$11.4M$8.71M
Long-term debt$1.99M$2.09M$1.75M$2.27M$2.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$56.9M$32.7M$10.8M$2.44M$2.87M
Capital lease obligations$2.73M$2.61M$2.31M$2.8M$3.31M
Total liabilities$97.5M$47.7M$22.4M$13.9M$11.6M
Common stock$120K$120K$110K$110K$110K
Retained earnings-$-177.57M-$-143.29M-$-111.89M-$-97.51M-$-77.59M
Accumulated other comprehensive income (loss)$0.00$10K$0.00$0.00$0.00
Total equity-$-26.02M$18.7M$47.2M$42M$54.9M
Total investments$5M$7.35M$3.94M$440K$0.00
Total debt$2.73M$2.61M$2.31M$2.8M$3.31M
Net debt-$-10.24M-$-13.65M-$-18.31M-$-11.87M-$-28.32M
Cash flow statement
20252024202320222021
Net income-$-34.28M-$-31.4M-$-14.38M-$-19.91M-$-19.6M
Depreciation and amortization$4.5M$3.93M$3.52M$3.41M$2.76M
Stock-based compensation$3.14M$2.67M$5.54M$6.61M$6.87M
Change in working capital$1.1M-$-3.04M-$-7.78M-$-5.58M-$-40K
Accounts receivable$290K-$-2.1M$1.08M-$-1.44M-$-2.65M
Inventory-$-13.9M-$-4.9M-$-7.46M-$-6.89M$2.33M
Accounts payable$13M$1.96M-$-1.42M$2.73M$210K
Net cash provided by operating activities-$-14.83M-$-2.27M-$-9.66M-$-14.86M-$-8.97M
Investments in property, plant and equipment-$-80K-$-160K-$-240K-$-120K-$-350K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$1.28M-$-2.16M-$-4.16M-$-120K-$-350K
Common stock issued$260K$60K$5.88M$410K$360K
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.3M$80K$19.8M-$-1.99M$360K
Net change in cash-$-3.29M-$-4.36M$5.95M-$-16.96M-$-8.96M
Cash at end of period$13M$16.3M$20.6M$14.7M$31.6M
Operating cash flow-$-14.83M-$-2.27M-$-9.66M-$-14.86M-$-8.97M
Capital expenditure-$-80K-$-160K-$-240K-$-120K-$-350K
Free cash flow-$-14.91M-$-2.43M-$-9.89M-$-14.97M-$-9.32M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LENSAR Inc

        LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing laser systems for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism in the United System, Europe, Asia, South Korea, and internationally. The company offers the LENSAR Laser System, which incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes by providing imaging, procedure planning, design, and precision. It also provides ALLY Robotic Cataract Laser System, a compact cataract treatment system that is designed to allow surgeons to perform sterile laser-assisted cataract surgery in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

        CEO
        Nicholas T. Curtis
        Employees
        150
        Beta
        0.87

        Explore

        Frequently asked questions

        What is the intrinsic value of LENSAR Inc (LNSR)?

        LENSAR Inc (LNSR) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LNSR undervalued?

        LNSR trades at a price of $4.46 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.